Trust Asset Management LLC Sells 1,879 Shares of Johnson & Johnson (NYSE:JNJ)

Trust Asset Management LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 6.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,012 shares of the company’s stock after selling 1,879 shares during the quarter. Johnson & Johnson makes up 0.4% of Trust Asset Management LLC’s portfolio, making the stock its 21st biggest position. Trust Asset Management LLC’s holdings in Johnson & Johnson were worth $4,391,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. LaFleur & Godfrey LLC increased its holdings in shares of Johnson & Johnson by 4.9% during the third quarter. LaFleur & Godfrey LLC now owns 118,918 shares of the company’s stock valued at $18,521,000 after acquiring an additional 5,585 shares in the last quarter. Hanlon Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 46.3% during the third quarter. Hanlon Investment Management Inc. now owns 2,081 shares of the company’s stock valued at $324,000 after acquiring an additional 659 shares in the last quarter. Kessler Investment Group LLC boosted its position in shares of Johnson & Johnson by 1.9% during the third quarter. Kessler Investment Group LLC now owns 52,455 shares of the company’s stock valued at $8,170,000 after buying an additional 974 shares during the last quarter. Proficio Capital Partners LLC boosted its position in shares of Johnson & Johnson by 1.5% during the third quarter. Proficio Capital Partners LLC now owns 21,097 shares of the company’s stock valued at $3,286,000 after buying an additional 306 shares during the last quarter. Finally, Capital Advisory Group Advisory Services LLC purchased a new stake in shares of Johnson & Johnson during the third quarter valued at $1,260,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 1.5 %

NYSE JNJ opened at $144.61 on Wednesday. The stock’s 50-day moving average price is $154.80 and its 200-day moving average price is $155.14. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The company has a market capitalization of $348.48 billion, a P/E ratio of 9.02, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.68 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.43%. The ex-dividend date is Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is 29.68%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JNJ. Raymond James increased their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, April 15th. Royal Bank of Canada dropped their price objective on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 17th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Finally, Morgan Stanley dropped their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $175.86.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.